Cwm LLC Acquires 5,041 Shares of Eli Lilly and Company (NYSE:LLY)

Cwm LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 7.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,862 shares of the company’s stock after purchasing an additional 5,041 shares during the quarter. Cwm LLC’s holdings in Eli Lilly and Company were worth $53,572,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Moseley Investment Management Inc. raised its position in Eli Lilly and Company by 0.4% during the first quarter. Moseley Investment Management Inc. now owns 3,890 shares of the company’s stock worth $3,027,000 after acquiring an additional 14 shares in the last quarter. Advance Capital Management Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter valued at $223,000. Orrstown Financial Services Inc. increased its holdings in shares of Eli Lilly and Company by 2.6% in the first quarter. Orrstown Financial Services Inc. now owns 824 shares of the company’s stock valued at $641,000 after purchasing an additional 21 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after purchasing an additional 13 shares during the last quarter. Finally, Waller Financial Planning Group Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter valued at $214,000. 82.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the transaction, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Johna Norton sold 7,056 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 762,804 shares of company stock worth $648,109,138. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Up 0.7 %

Shares of NYSE LLY opened at $891.46 on Thursday. The company has a 50 day simple moving average of $793.39 and a 200 day simple moving average of $724.73. The firm has a market cap of $847.25 billion, a PE ratio of 131.29, a price-to-earnings-growth ratio of 1.94 and a beta of 0.36. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $894.87. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the business earned $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. On average, research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a dividend of $1.30 per share. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 annualized dividend and a yield of 0.58%. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Ratings Changes

LLY has been the topic of several research reports. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. BMO Capital Markets upped their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $787.53.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.